| Patient | Ann Richards |
|---|---|
| Date of birth | 1933-09-01 |
| Identifiers | MRN HR-ML019-SYN-TD; SSN (made up) 000-19-3381 |
| Document date | 1997-03-10 |
| Author | Rosalind Teague, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week bone health review. [S]
Ms. Richards returns four weeks after her intake visit. She takes vitamin D3 1971 units every day. She has added yogurt, cheese, and calcium-fortified orange juice, and her three-day food record shows about 1200 mg of calcium a day. She keeps walking and lifting weights and has had no falls. She did not collect the 24-hour urine sample before this visit because she was traveling for three weeks. She saw the endocrinologist this morning. Her balance and strength program with the physical therapist starts next week, and she has a routine dental examination booked next month. She has had no alcohol and no cravings. [S]
| Element | Detail |
|---|---|
| Calcium intake | About 1200 mg a day from food by three-day record |
| Vitamin D | D3 1971 units daily, no missed doses |
| Falls | None |
| Pending tests | 24-hour urine calcium not yet collected |
| Recovery | No alcohol; no cravings |
| System | Result | Finding |
|---|---|---|
| Musculoskeletal | Negative | No back pain, new bone pain, or fracture; the healed hand is not painful |
| Neurological | Negative | No dizziness or unsteadiness |
| Gastrointestinal | Negative | No constipation since adding dairy foods |
| Psychiatric | Negative | Mood good; no cravings; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol (vitamin D3) 50 mcg (1971 units) oral tablet, one tablet daily | One tablet by mouth daily | Oral route | 1997-02-10 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1997-03-10 | Body height | 164 | cm | S |
| 1997-03-10 | Body weight | 66.2 | kg | S |
| 1997-03-10 | Body mass index (BMI) [Ratio] | 24.6 | kg/m2 | S |
| 1997-03-10 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1997-03-10 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1997-03-10 | Heart rate | 70 | /min | S |
| 1997-03-10 | Respiratory rate | 14 | /min | S |
| 1997-03-10 | Body temperature | 36.7 | Cel | S |
| 1997-03-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Vital signs recorded on 1997-03-10; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and animated; weight 66.2 kg |
| Spine | No tenderness or kyphosis; occiput touches the wall |
| Gait and balance | Gait steady; tandem stance 8 seconds, unchanged |
| Mouth | Good dentition; no exposed bone or gum swelling |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Low bone mass (osteopenia) of the lumbar spine and hip on DXA, lowest T-score -2.3 at the lumbar spine (femoral neck -2.0, total hip -1.7), with a 10-year FRAX risk above the treatment thresholds (major osteoporotic fracture 22 percent, hip 3.6 percent); not osteoporosis by T-score, but meets the AACE 1991 clinical criteria for osteoporosis (low bone mass with a FRAX risk above threshold) | active | confirmed | M85.89 | S — Synthetic modern DXA and FRAX classification linked to her publicly described osteopenia (early osteoporosis) after a fall with a hand fracture. |
| Alcohol use disorder in sustained remission for more than fifteen years, since treatment; no alcohol since | active | confirmed | F10.21 | S — Synthetic modern coding of her publicly described heavy drinking and long recovery; listed because remission protects bone and lowers fall risk, and it is reviewed at each visit. |
| History of falls: a fall from standing height with a hand fracture last year (and, in one account, a second fall with an ankle fracture); no falls since | active | confirmed | Z91.81 | S — Synthetic modern entry linked to her publicly described falls and fractures. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Secondary-causes work-up | At diagnosis: calcium, albumin, phosphate, magnesium, alkaline phosphatase, creatinine and eGFR, PTH, 25-hydroxyvitamin D, TSH, blood count, and 24-hour urine calcium | Up to date | At intake: calcium 9.4 mg/dL, albumin 4.2 g/dL, phosphate 3.5, magnesium 2.0, alkaline phosphatase 84 U/L, creatinine 0.8 mg/dL (eGFR 81), PTH 54 pg/mL, TSH 1.9, hemoglobin 13.3, all normal; 25-hydroxyvitamin D 24 ng/mL, low |
| Laboratory | 24-hour urine calcium | At diagnosis, before starting therapy | Deferred | Ordered at intake to be collected before today; not collected because she was traveling. Deviation from the baseline work-up. No harm so far, because no drug has been started. Corrective action: container and instructions given again, and the result is required before the first infusion |
| Laboratory | 25-hydroxyvitamin D | At baseline; after repletion until 30 ng/mL or more; then yearly | Due | 24 ng/mL at intake; recheck at three months, before the first infusion |
| Laboratory | Serum calcium before each intravenous antiresorptive dose | Before each zoledronic acid dose | Due | Planned at three months, before the first infusion |
| Laboratory | Bone-turnover marker (fasting serum CTX) | Baseline, then 3 to 6 months after starting or changing therapy | Up to date | 560 pg/mL at intake; repeat three months after the first dose |
| Imaging | Central DXA of the spine and hip | Every 1 to 2 years on therapy until stable, on the same scanner | Up to date | Baseline at intake; repeat two years after starting therapy |
| Imaging | Vertebral fracture assessment | At baseline with a recent low-trauma fracture, height loss of 4 cm or more, or a T-score of -2.5 or lower | Up to date | Done at intake for the recent low-trauma fracture: no vertebral fracture |
| Examination | Standing height by stadiometer | Yearly; vertebral imaging again if height falls 2 cm or more | Up to date | 164.0 cm at intake |
| Examination | Fall-risk screen | Yearly, and with any fall | Up to date | At intake: Timed Up and Go 11 seconds, tandem stance 8 seconds, chair stand 11; fall with fracture in the past year |
| Survey | FRAX 10-year fracture risk | At baseline and when risk factors change | Up to date | 22 percent major osteoporotic and 3.6 percent hip at intake; no change in risk factors |
| Survey | Calcium intake assessment | At baseline and yearly | Completed today | About 1200 mg a day from food by three-day record, up from about 800 mg |
| Medication safety | Dental examination before an antiresorptive | Before starting a bisphosphonate or denosumab | Due | Routine dental examination booked next month, before the first infusion |
| Medication safety | Drug-holiday eligibility | After 3 yearly zoledronic acid doses or 5 years of an oral bisphosphonate | Not indicated | No drug started yet |
| Medication safety | Denosumab continuity check | Every 6 months on denosumab | Not indicated | Not on denosumab |
| Referral | Endocrinology consultation | When the diagnosis, risk category, or drug choice needs specialist review | Completed today | Seen today; treatment indicated; zoledronic acid recommended after vitamin D repletion |
| Self-management | Balance and strength exercise program | With a history of falls or impaired balance | Referred | Physical therapist program begins next week |
| Self-management | Recovery check (alcohol, cravings, stress) | Every visit | Completed today | No alcohol; no cravings |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in her phone |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); The clinician's guide to prevention and treatment of osteoporosis (2022); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020); Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019); STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Balance program from next week. Dental examination next month. 24-hour urine collection before the next visit. Bone health review in two months with pre-infusion tests and the first infusion. Next scheduled visit 1997-05-12: three-month bone health review and first zoledronic acid infusion. [S]